Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

NEW YORK, Oct. 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

http://www.reportlinker.com/p0660751/Anti-Inflammatory-Therapeutics-Market-to-2017---Respiratory-Diseases-and-Arthritis-Continue-to-Dominate.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate", which provides insights into anti-inflammatory therapeutics revenue forecasts until 2017. The report also examines the global anti-inflammatory treatment usage patterns. In addition, the geographical distribution of anti-inflammatory therapies across the US, the top five countries in Europe, and Japan is also provided in the report. The report also includes insights into the anti-inflammatory R&D pipeline. The report provides an in-depth analysis of the top seven inflammatory therapeutic indications, which are respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout. Furthermore, it also includes the market forecasts and treatment usage patterns of these seven therapeutic indications. The report also explores the competitive landscape, including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&As) and licensing agreements involving anti-inflammatory treatments is also presented.

The in-depth analysis of the report is based on proprietary databases, primary and secondary research, and in-house analysis by the GBI Research team of experts.

GBI Research analysis showed that the global inflammatory therapeutics market was estimated at $57.8 billion in 2010, representing a cumulative annual growth rate of 7.6% between 2002 and 2010. GBI Research forecasts that the market will grow at a Compound Annual Growth Rate (CAGR) of 5.8% between 2010 and 2017, to record a sales value of $85.9 billion. The patent expiry of some major drugs by 2017 is expected to make way for the entry of generics, whereas this impact will be reversed by a number of strong pipeline molecules.

GBI Research has segmented each section of the anti-inflammatory therapeutics market into branded and generics, and estimates the global inflammatory therapeutics to gain 73.1% of revenue from the branded market, whereas 26.9% was achieved from the generics market in 2010. Due to the presence of a strong pipeline portfolio for anti-inflammatories, the branded share is forecast to increase to 78.6% in 2017, and the generics market will decrease to 21.4%.

GBI Research analysis shows that the R&D pipeline for anti-inflammatory therapeutics is strong. Many of the major pharmaceutical companies such as Abbott, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Eli Lilly, Boehringer Ingelheim and Sanofi are either entering or expanding into the market. They are collaborating with or acquiring small and medium-sized enterprise (SME) pharmaceuticals, which have promising anti-inflammatory drugs in their pipeline. Currently, more than 1,000 molecules are in R&D, with 12% of them in Phase III, 36% in Phase II, 15% in Phase I, 29% in preclinical stage, and 7% in discovery phase. This indicates that anti-inflammatory R&D will be very active for at least the next seven to eight years. The main factor that is driving the big pharmaceutical companies towards the inflammatory therapeutics market is the large patient base. Respiratory diseases and arthritis continue to be some of the most common diseases and are among the leading causes behind major chronic disabilities in the workforce.

Scope

- Data and analysis on the inflammatory therapeutics market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.

- Annualized market data for the inflammatory therapeutics market from 2002 to 2010, with forecasts to 2017.

- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.

- Analysis of the leading therapeutic segments, including respiratory diseases, arthritis, multiple sclerosis, psoriasis, spondyloarthropathies, inflammatory bowel disease and gout.

- Key drivers and restraints that have a significant impact on the market.

- The competitive landscape of the global inflammatory therapeutics market, including top companies benchmarking. The key companies studied in this report are Abbott, Amgen Inc., Johnson & Johnson, GlaxoSmithKline, AstraZeneca, Merck, Pfizer, Eli Lilly, Boehringer Ingelheim and Sanofi.

- Key M&A activities and Licensing Agreements that took place in 2004 and 2010 in the inflammatory therapeutics market.

Reasons to buy

- Build effective strategies to launch their pipeline products by identifying potential geographies.

- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.

- Develop key strategic initiatives by studying the key strategies of top competitors.

- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 7

1.2 List of Figures 10

2 Anti-Inflammatory Therapeutics Market to 2017: Introduction 12

2.1 GBI Research Report Guidance 13

3 Anti-Inflammatory Therapeutics Market to 2017: Market Overview 14

3.1 Introduction 14

3.1.1 Revenue 14

3.1.2 Branded Vs Generics 15

3.1.3 Annual Cost of Treatment 16

3.1.4 Treatment Usage Pattern 17

4 Anti-Inflammatory Therapeutics Market to 2017: Geographical Landscape 19

4.1 Revenue Analysis by Geography 19

4.2 The US 21

4.2.1 Revenue 21

4.2.2 Annual Cost of Treatment 22

4.2.3 Treatment Usage Patterns 23

4.3 Top Five Countries of Europe 25

4.3.1 Revenue 25

4.3.2 Annual Cost of Treatment 28

4.3.3 Treatment Usage Patterns 30

4.4 Japan 32

4.4.1 Revenue 32

4.4.2 Annual Cost of Treatment 33

4.4.3 Treatment Usage Patterns 34

5 Anti-Inflammatory Therapeutics Market to 2017: Therapeutic Landscape 36

5.1 Respiratory Diseases 36

5.1.1 Introduction 36

5.1.2 Revenue 36

5.1.3 Annual Cost of Treatment 40

5.1.4 Treatment Usage Pattern 41

5.2 Drivers and Barriers the Respiratory Therapeutics Market 43

5.2.1 Drivers for Respiratory Therapeutics Market 43

5.2.2 Barriers for Respiratory Therapeutics Market 44

5.3 Arthritis Therapeutics Market 45

5.3.1 Introduction 45

5.3.2 Revenue 45

5.3.3 Annual Cost of Treatment 48

5.3.4 Treatment Usage Pattern 49

5.4 Drivers and Barriers for Arthritis Therapeutics Market 51

5.4.1 Drivers for Arthritis Therapeutics Market 51

5.4.2 Barriers for Arthritis Therapeutics Market 52

5.5 Multiple Sclerosis Therapeutics 53

5.5.1 Introduction 53

5.5.2 Revenue 55

5.5.3 Annual Cost of Treatment 58

5.5.4 Treatment Usage Pattern 59

5.6 Drivers and Barriers for Multiple Sclerosis Therapeutics Market 61

5.6.1 Drivers for Multiple Sclerosis Therapeutics Market 61

5.6.2 Barriers for Multiple Sclerosis Therapeutics Market 62

5.7 Psoriasis Therapeutics Market 63

5.7.1 Introduction 63

5.7.2 Revenue 64

5.7.3 Annual Cost of Treatment 67

5.7.4 Treatment Usage Pattern 68

5.8 Drivers and Barriers for Psoriasis Therapeutics Market 70

5.8.1 Drivers for Psoriasis Therapeutics Market 70

5.8.2 Barriers for Psoriasis Therapeutics Market 71

5.9 Spondyloarthropathies Therapeutics Market 71

5.9.1 Introduction 71

5.9.2 Revenue 72

5.9.3 Treatment Usage Pattern 76

5.10 Drivers and Barriers for Spondyloarthropathies Therapeutics Market 78

5.10.1 Drivers for Spondyloarthropathies Therapeutics Market 78

5.10.2 Barriers for Spondyloarthropathies Therapeutics Market 79

5.11 Inflammatory Bowel Disease 79

5.11.1 Introduction 79

5.11.2 Revenue 81

5.11.3 Annual Cost of Treatment 84

5.11.4 Treatment Usage Pattern 85

5.12 Drivers and Barriers for IBD Therapeutics Market 87

5.12.1 Drivers the IBD Therapeutics Market 87

5.12.2 Barriers for IBD Therapeutics Market 88

5.13 Gout Therapeutics Market 88

5.13.1 Introduction 88

5.13.2 Revenue 91

5.13.3 Annual Cost of Treatment (ACT) 94

5.13.4 Treatment Usage Pattern 95

5.14 Drivers and Barriers for Gout Therapeutics Market 97

5.14.1 Drivers for Gout Therapeutics Market 98

5.14.2 Barriers for Gout Therapeutics Market 98

6 Anti-Inflammatory Therapeutics Market to 2017: Pipeline Analysis 99

6.1 Introduction 99

6.2 Anti-Inflammatory Therapeutics Market to 2017 – Pipeline Assessment by Clinical Phase of Development 101

6.2.1 Filed Molecules 101

6.2.2 Phase III 102

6.2.3 Phase II 111

6.2.4 Phase I 136

6.2.5 Preclinical Phase 145

6.2.6 Discovery Phase 173

6.3 Anti-Inflammatory Therapeutics Market to 2017 – Profiles of Promising Molecules 178

6.3.1 Indacaterol 178

6.3.2 BTR-15K 179

6.3.3 Flutiform 180

6.3.4 Iguratimod 181

6.3.5 OHR/AVR118 182

6.3.6 Simponi 183

6.3.7 Zushima 184

6.3.8 Civanex 184

6.3.9 Naproxcinod 185

6.3.10 Gilenia 187

6.3.11 Cladribine 187

6.3.12 Fampyra 189

6.3.13 LAS41002 189

6.3.14 BTR-15K 190

6.3.15 XOMA 052 191

7 Anti-Inflammatory Therapeutics Market to 2017: Competitive Profiling 193

7.1 Abbott Laboratories 193

7.1.1 Company Overview 193

7.1.2 Marketed Products 193

7.1.3 SWOT Analysis 193

7.2 Amgen Inc. 194

7.2.1 Company Overview 194

7.2.2 Marketed Products 194

7.2.3 SWOT Analysis 194

7.3 Johnson & Johnson 195

7.3.1 Company Overview 195

7.3.2 Marketed Products 195

7.3.3 SWOT Analysis 195

7.4 GlaxoSmithKline 196

7.4.1 Company Overview 196

7.4.2 Marketed Products 196

7.5 AstraZeneca 197

7.5.1 Company Overview 197

7.5.2 Marketed Products 197

7.5.3 SWOT Analysis 198

7.6 Merck 199

7.6.1 Company Overview 199

7.6.2 Marketed Products 199

7.6.3 SWOT Analysis 200

7.7 Pfizer 200

7.7.1 Company Overview 200

7.7.2 Marketed Products 200

7.7.3 SWOT Analysis 201

7.8 Boehringer Ingelheim GmbH 201

7.8.1 Company Overview 201

7.8.2 Marketed Products 201

7.8.3 SWOT Analysis 202

7.9 Sanofi 202

7.9.1 Company Overview 202

7.9.2 Marketed Products 202

7.9.3 SWOT Analysis 203

8 Anti-Inflammatory Therapeutics Market to 2017: Strategic Consolidations 204

8.1 M&A Deals 205

8.1.1 Deals by Year 205

8.1.2 Deals by Geography 206

8.1.3 Deals by Value ($) 207

8.1.4 Merck & Co Completes Merger with Schering-Plough 207

8.1.5 Pfizer Completes Acquisition of Wyeth 207

8.1.6 Bayer Acquires Schering 208

8.2 Licensing Agreements 208

8.2.1 Deals by Year 208

8.2.2 Deals by Geography 209

8.2.3 Deals by Value ($) 210

8.2.4 Incyte Enters Into Licensing Agreement with Pfizer 210

8.2.5 Orexo Enters Into Licensing Agreement with Ortho-McNeil-Janssen and Janssen Pharmaceutica 211

8.2.6 Cytos Biotechnology Plans to Enter Into Licensing Agreement for CYT003-QbG10 211

8.3 Co-Developments 212

8.3.1 Deals by Year 212

8.3.2 Deals by Geography 213

8.3.3 Deals by Value ($) 214

8.3.4 Galapagos Enters Into Strategic Alliance with Roche Holding 214

8.3.5 Sepracor Enters Into Co-Development Agreement with Nycomed 215

8.3.6 Galapagos Extends its Co-Development Agreement with GlaxoSmithKline 215

8.3.7 Lycera Enters Into Research Agreement with Merck 215

9 Anti-Inflammatory Therapeutics Market to 2017: Appendix 216

9.1 Market Definitions 216

9.2 Abbreviations 216

9.3 Research Methodology 217

9.3.1 Coverage 217

9.3.2 Secondary Research 218

9.3.3 Primary Research 218

9.3.4 Therapeutic Landscape 219

9.3.5 Market Size by Geography 220

9.3.6 Geographical Landscape 222

9.3.7 Pipeline Analysis 222

9.3.8 Competitive Landscape 222

9.3.9 Expert Panel Validation 222

9.4 Contact Us 222

9.5 Disclaimer 222

9.6 Sources 223

1.1 List of Tables

Table 1: Anti-Inflammatory Therapeutics Market, Global, Revenue ($bn), 2002-2010 14

Table 2: Anti-Inflammatory Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 14

Table 3: Anti-Inflammatory Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 16

Table 4: Anti-Inflammatory Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 16

Table 5: Anti-Inflammatory Therapeutics Market, Global, Treatment Usage Patterns (millions), 2002-2010 17

Table 6: Anti-Inflammatory Therapeutics Market, Global, Treatment Usage Patterns (millions), 2010-2017 18

Table 7: Anti-Inflammatory Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2010 20

Table 8: Anti-Inflammatory Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2010-2017 20

Table 9: Anti-Inflammatory Therapeutics Market, The US, Revenue ($bn), 2002-2010 21

Table 10: Anti-Inflammatory Therapeutics Market, The US, Revenue Forecast($bn), 2010-2017 21

Table 11: Anti-Inflammatory Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2010 22

Table 12: Anti-Inflammatory Therapeutics Market, The US, Annual Cost of Treatment ($), 2010-2017 22

Table 13: Anti-Inflammatory Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2010 23

Table 14: Anti-Inflammatory Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2017 24

Table 15: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2010 26

Table 16: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Forecast ($bn), 2010-2017 26

Table 17: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Segmentation by Geography ($bn), 2002-2010 27

Table 18: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Segmentation by Geography ($bn), 2010-2017 27

Table 19: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2010 29

Table 20: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2010-2017 29

Table 21: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2002-2010 30

Table 22: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2010-2017 31

Table 23: Anti-Inflammatory Therapeutics Market, Japan, Revenue ($bn), 2002-2010 32

Table 24: Anti-Inflammatory Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2017 32

Table 25: Anti-Inflammatory Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2010 33

Table 26: Anti-Inflammatory Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2017 33

Table 27: Anti-Inflammatory Therapeutics Market, Japan, Treatment Usage Pattern (millions), 2002-2010 34

Table 28: Anti-Inflammatory Therapeutics Market, Japan, Treatment Usage Pattern (millions), 2010-2017 35

Table 29: Respiratory Therapeutics Market, Global, Revenues ($bn), 2002-2010 37

Table 30: Respiratory Therapeutics Market, Global, Revenue Forecast($bn), 2010-2017 37

Table 31: Respiratory Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 38

Table 32: Respiratory Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 39

Table 33: Respiratory Therapeutics Market, Global, Average Cost of Treatment ($), 2002-2010 40

Table 34: Respiratory Therapeutics Market, Global, Average Cost of Treatment ($), 2010-2017 40

Table 35: Respiratory Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 42

Table 36: Respiratory Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 42

Table 37: Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2010 45

Table 38: Arthritis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 45

Table 39: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 46

Table 40: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 47

Table 41: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 48

Table 42: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 48

Table 43: Arthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 49

Table 44: Arthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 50

Table 45: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2002-2010 55

Table 46: Multiple Sclerosis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 55

Table 47: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 56

Table 48: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 57

Table 49: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 58

Table 50: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 58

Table 51: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2010 59

Table 52: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2010-2017 60

Table 53: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002-2010 64

Table 54: Psoriasis Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 64

Table 55: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 65

Table 56: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 66

Table 57: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 67

Table 58: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 67

Table 59: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 68

Table 60: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 69

Table 61: Spondyloarthropathies Therapeutics Market, Global, Revenue ($bn), 2002-2010 72

Table 62: Spondyloarthropathies Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 72

Table 63: Spondyloarthropathies Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 73

Table 64: Spondyloarthropathies Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 73

Table 65: Spondyloarthropathies Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 75

Table 66: Spondyloarthropathies Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 75

Table 67: Spondyloarthropathies Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 76

Table 68: Spondyloarthropathies Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 77

Table 69: IBD Therapeutics Market, Global, Revenue ($bn), 2002-2010 81

Table 70: IBD Therapeutics Market, Global, Revenue Forecast ($bn), 2010-2017 81

Table 71: IBD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 82

Table 72: IBD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 83

Table 73: IBD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 84

Table 74: IBD Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 84

Table 75: IBD Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2010 85

Table 76: IBD Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2010-2017 86

Table 77: Gout Therapeutics Market, Global, Revenue ($m), 2002-2010 91

Table 78: Gout Therapeutics Market, Global, Revenue Forecast ($m), 2010-2017 91

Table 79: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2010 92

Table 80: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2010-2017 92

Table 81: Gout Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2010 94

Table 82: Gout Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-2017 94

Table 83: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2010 95

Table 84: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2010-2017 96

Table 85: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, NDA Filed Molecules 101

Table 86: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Phase III 102

Table 87: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Phase II 111

Table 88: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Phase I 136

Table 89: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Preclinical Phase 145

Table 90: Anti-Inflammatory Therapeutics Market, Global, Pipeline Analysis, Discovery Phase 173

1.2 List of Figures

Figure 1: Anti-Inflammatory Therapeutics Market, Global, Therapeutic Market Share (%), 2010 12

Figure 2: Anti-Inflammatory Therapeutics Market, Global, Revenue ($bn), 2002-2017 14

Figure 3: Anti-Inflammatory Therapeutics Market, Global, Revenue Segmentation, 2010-2017 15

Figure 4: Anti-Inflammatory Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 16

Figure 5: Anti-Inflammatory Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 17

Figure 6: Anti-Inflammatory Therapeutics Market, Global, Revenue Analysis by Geography ($bn), 2002-2017 19

Figure 7: Anti-Inflammatory Therapeutics Market, The US, Revenue ($bn), 2002-2017 21

Figure 8: Anti-Inflammatory Therapeutics Market, The US, Annual Cost of Treatment ($), 2002-2017 22

Figure 9: Anti-Inflammatory Therapeutics Market, The US, Treatment Usage Patterns (millions), 2002-2017 23

Figure 10: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue ($bn), 2002-2017 25

Figure 11: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Revenue Segmentation by Geography ($bn), 2002-2017 26

Figure 12: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 28

Figure 13: Anti-Inflammatory Therapeutics Market, Top Five Countries of Europe, Treatment Usage Pattern (millions), 2002-2017 30

Figure 14: Anti-Inflammatory Therapeutics Market, Japan, Revenue Forecast ($bn), 2002-2017 32

Figure 15: Anti-Inflammatory Therapeutics Market, Japan, Annual Cost of Treatment ($), 2002-2017 33

Figure 16: Anti-Inflammatory Therapeutics Market, Japan, Treatment Usage Pattern (millions), 2002-2017 34

Figure 17: Respiratory Therapeutics Market, Global, Revenue ($bn), 2002-2017 36

Figure 18: Respiratory Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 38

Figure 19: Respiratory Therapeutics Market, Global, Revenue Segmentation, 2010-2017 39

Figure 20: Respiratory Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 40

Figure 21: Respiratory Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 41

Figure 22: Respiratory Diseases Therapeutics Market, Drivers and Barriers, 2010-2017 43

Figure 23: Arthritis Therapeutics Market, Global, Revenue ($bn), 2002-2017 45

Figure 24: Arthritis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 46

Figure 25: Arthritis Therapeutics Market, Global, Revenue Segmentation, 2010-2017 47

Figure 26: Arthritis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 48

Figure 27: Arthritis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017 49

Figure 28: Arthritis Therapeutics Market, Market Drivers and Barriers, 2010-2017 51

Figure 29: Multiple Sclerosis Therapeutics Market, Global, Revenue ($bn), 2002-2017 55

Figure 30: Multiple Sclerosis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 56

Figure 31: Multiple Sclerosis Therapeutics Market, Global, Revenue Segmentation, 2010-2017 57

Figure 32: Multiple Sclerosis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 58

Figure 33: Multiple Sclerosis Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2017 59

Figure 34: Multiple Sclerosis Therapeutics Market, Drivers and Barriers, 2010-2017 61

Figure 35: Psoriasis Therapeutics Market, Global, Revenue ($bn), 2002-2017 64

Figure 36: Psoriasis Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 65

Figure 37: Psoriasis Therapeutics Market, Global, Revenue Segmentation, 2010-2017 66

Figure 38: Psoriasis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 67

Figure 39: Psoriasis Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017 68

Figure 40: Psoriasis Therapeutics Market, Drivers and Barriers, 2010-2017 70

Figure 41: Spondyloarthropathies Therapeutics Market, Global, Revenue ($bn), 2002-2017 72

Figure 42: Spondyloarthropathies Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 73

Figure 43: Spondyloarthropathies Therapeutics Market, Global, Revenue Segmentation, 2010-2017 74

Figure 44: Spondyloarthropathies Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 75

Figure 45: Spondyloarthropathies Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017 76

Figure 46: Spondyloarthropathies Therapeutics Market, Global, Drivers and Barriers, 2010-2017 78

Figure 47: IBD Therapeutics Market, Global, Revenue ($bn), 2002-2017 81

Figure 48: IBD Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 82

Figure 49: IBD Therapeutics Market, Global, Revenue Segmentation, 2010-2017 83

Figure 50: IBD Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 84

Figure 51: IBD Therapeutics Market, Global, Treatment Usage Pattern (thousands), 2002-2017 85

Figure 52: IBD Therapeutics Market, Global, Drivers and Barriers, 2010-2017 87

Figure 53: Gout Therapeutics Market, Global, Revenue ($m), 2002-2017 91

Figure 54: Gout Therapeutics Market, Global, Revenue Analysis by Geography ($m), 2002-2017 92

Figure 55: Gout Therapeutics Market, Global, Revenue Segmentation, 2010-2017 93

Figure 56: Gout Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-2017 94

Figure 57: Gout Therapeutics Market, Global, Treatment Usage Pattern (millions), 2002-2017 95

Figure 58: Gout Therapeutics Market, Global, Drivers and Barriers, 2010-2017 97

Figure 59: Anti-Inflammatory Therapeutics Market, Global, R&D Pipeline by Indications, 2010 99

Figure 60: Anti-Inflammatory Therapeutics Market, Global, R&D Pipeline by Phase, 2010 100

Figure 61: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Abbott, 2011 193

Figure 62: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Amgen Inc., 2011 194

Figure 63: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Johnson & Johnson, 2011 195

Figure 64: Anti-Inflammatory Therapeutics Market, SWOT Analysis, GlaxoSmithKline, 2011 197

Figure 65: Anti-Inflammatory Therapeutics Market, SWOT Analysis, AstraZeneca, 2011 198

Figure 66: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Merck, 2011 200

Figure 67: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Pfizer, 2011 201

Figure 68: Anti-Inflammatory Therapeutics Market, SWOT Analysis, Boehringer Ingelheim GmbH, 2011 202

Figure 69: Anti-Infllamtory Therapeutics Market, SWOT Analysis, Sanofi, 2011 203

Figure 70: Anti-Inflammatory Therapeutics Market, Global, Deals by Type, 2004-2011 204

Figure 71: Anti-Inflammatory Therapeutics Market, Global, Major Deals By Year, 2004-2011 205

Figure 72: Anti-Inflammatory Therapeutics Market, Global, Major Deals By Geography, 2004-2011 206

Figure 73: Anti-Inflammatory Therapeutics Market, Global, Major Deals by Value (%), 2004–2011 207

Figure 74:Anti-Inflammatory Therapeutics Market, Global, Licensing Deals By Year, 2004-2010 208

Figure 75: Anti-Inflammatory Therapeutics Market, Global, Licensing Deals By Geography, 2004-2011 209

Figure 76: Anti-Inflammatory Therapeutics Market, Global, Major Licensing Deals by Value (%), 2004–2011 210

Figure 77: Anti-Inflammatory Therapeutics Market, Global, Co-Development Deals By Year, 2004-2010 212

Figure 78: Anti-Inflammatory Therapeutics Market, Global, Co-Development Deals By Geography, 2004-2010 213

Figure 79: Anti-Inflammatory Therapeutics Market, Global, Major Co-Development Deals by Value (%), 2004–2010 214

Figure 80: GBI Research Market Forecasting Model 221

Companies Mentioned

Abbott Laboratories

Amgen Inc.

Johnson & Johnson

GlaxoSmithKline

AstraZeneca

Merck

Pfizer

Boehringer Ingelheim GmbH

Sanofi

To order this report:

Pathology Industry: Anti-Inflammatory Therapeutics Market to 2017 - Respiratory Diseases and Arthritis Continue to Dominate

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker